Healthline
December 10, 2024
Share on PinterestNew research suggests that consuming sugar-sweetened drinks may raise your risk of cardiovascular disease, while eating the occasional sweet treat will not. Westend61/Getty Images […]
December 7, 2024
Share on PinterestNurse practitioner Tim Nicaise tried everything to lose weight without success. Then his doctor prescribed the drug Contrave and his life changed. Image Provided […]
December 7, 2024
Share on PinterestThe 90-30-50 diet involves eating 90 grams of protein, 30 grams of fiber, and 50 grams of fat per day to promote weight loss. […]
December 6, 2024
Share on PinterestDrug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Shelby Knowles/Bloomberg via Getty Images Zepbound led […]
Medscape
February 20, 2025
TOPLINE: Adding aerobic physical activity to resistance exercise did not improve pain or function in patients with hip osteoarthritis (OA) after 3 months compared with resistance […]
February 20, 2025
TOPLINE: Obesity significantly reduced the effectiveness of febuxostat-based urate-lowering therapy among men with gout, with those with obesity showing lower target achievement rates and more flares […]
February 20, 2025
As burnout rates soar among oncologists and other healthcare professionals, 2025 kicked off with a dedicated 2-day meeting addressing this urgent issue. Organized by the European […]
February 20, 2025
In October, Stanford University professor Jay Bhattacharya hosted a conference on the lessons of COVID-19 in order “to do better in the next pandemic.” He invited […]
FDA
February 7, 2025
Docket Number: FDA-2011-D-0720 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Implementation of ICH E2B(R3) The E2B(R3) document package comprises four materials. The […]
February 6, 2025
On January 21, 2025, the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic […]
February 6, 2025
On January 27, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ […]
February 6, 2025
What are “Novel” Drugs? “Novel” drugs are new drugs never before approved or marketed in the U.S. See Drugs@FDA for information about all of CDER’s approved […]
